Genomma Lab Internacional SAB de CV
BMV:LABB

Watchlist Manager
Genomma Lab Internacional SAB de CV Logo
Genomma Lab Internacional SAB de CV
BMV:LABB
Watchlist
Price: 26.3 MXN 0.57% Market Closed
Market Cap: 26.8B MXN
Have any thoughts about
Genomma Lab Internacional SAB de CV?
Write Note

Gross Margin
Genomma Lab Internacional SAB de CV

63.1%
Current
61%
Average
48.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
63.1%
=
Gross Profit
10.6B
/
Revenue
16.8B

Gross Margin Across Competitors

Country MX
Market Cap 24.9B MXN
Gross Margin
63%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 710.5B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Country US
Market Cap 373.5B USD
Gross Margin
69%
Country US
Market Cap 251.1B USD
Gross Margin
77%
Country CH
Market Cap 202.7B CHF
Gross Margin
73%
Country CH
Market Cap 183.3B CHF
Gross Margin
75%
Country UK
Market Cap 162.4B GBP
Gross Margin
82%
Country IE
Market Cap 146B USD
Gross Margin
68%
No Stocks Found

Genomma Lab Internacional SAB de CV
Glance View

Market Cap
24.9B MXN
Industry
Pharmaceuticals

Genomma Lab Internacional SAB de CV engages in the development, manufacturing and marketing of pharmaceutical, beauty and personal care products. The company is headquartered in Mexico City, Mexico, D.F.. The company went IPO on 2008-06-19. The firm is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The firm is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.

LABB Intrinsic Value
26.75 MXN
Undervaluation 2%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
63.1%
=
Gross Profit
10.6B
/
Revenue
16.8B
What is the Gross Margin of Genomma Lab Internacional SAB de CV?

Based on Genomma Lab Internacional SAB de CV's most recent financial statements, the company has Gross Margin of 63.1%.